Navigation Links
Halozyme Therapeutics to Present at J.P. Morgan Healthcare Conference on January 12
Date:1/5/2011

SAN DIEGO, Jan. 5, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced its participation in the 29th Annual J.P. Morgan Healthcare Conference to be held on January 9-13, 2011 in San Francisco. Gregory Frost, Ph.D., president and CEO, will present an overview of Halozyme's business strategy and its product development pipeline on Wednesday, January 12, 2011 at 3:30 p.m. PST (6:30 p.m. EST). To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the company's Web site at www.halozyme.com. A replay will be available for 90 days after the event.

(Logo:  http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

About Halozyme Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets. The company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze™ technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche to apply Enhanze technology to Roche's biological therapeutics, including Herceptin® and MabThera®, and with Baxter BioScience to apply Enhanze technology to immunoglobulin. Halozyme's Ultrafast Insulin program combines its rHuPH20 enzyme with mealtime insulins, which may produce more rapid absorption, faster action, and improved glycemic control. The product candidates in Halozyme's pipeline target multiple areas of significant unmet medical need. For more information visit www.halozyme.com. Halozyme ContactRobert H. UhlSenior Director, Investor Relations(858) 704-8264ruhl@halozyme.com
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
2. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
3. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
4. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
5. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
6. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
7. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
8. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
9. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
10. Halozyme Provides HYLENEX® Product Reintroduction Update
11. Halozyme Therapeutics Announces Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... PARIS , May 25,2016 ... with the near-infrared Cellvizio platform for urological and ... MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary ... important regulatory milestone in the US with the ... Food and Drug Administration (FDA). This new FDA ...
(Date:5/25/2016)... and GERMANTOWN, Maryland , May 25, 2016 ... ; Frankfurt Prime Standard: QIA) today announced that the company ... Diagnostics GmbH to develop and commercialize predictive assays in oncology. ... as a marker to predict effectiveness of anthracycline treatment in ... "We are pleased to partner with Therawis, which developed the ...
(Date:5/25/2016)... NEW YORK , May 25, 2016 ... Device Market Size, Share, Development, Growth and Demand Forecast ... Insulin Syringe, Insulin Pump and Others)" published by P&S ... valued at $9,998.3 million in 2015, and it is ... 2016-2022. Based on type, the insulin pump segment is ...
Breaking Medicine Technology:
(Date:5/30/2016)... GA (PRWEB) , ... May 30, 2016 , ... ... on June 6th, while Shaolin warrior 8-day-8 and 8-night special intensive summer training ... Shaolin Institute annual overnight summer camp offers families and children a fun and ...
(Date:5/29/2016)... , ... May 29, 2016 , ... Whole Health Supply ... their new KlipPro KP-240L clipper is available to the public. This is an unusual ... substantially wider than the average clipper. , Everything about this product is concentrated on ...
(Date:5/28/2016)... ... May 28, 2016 , ... "Color Grading media can be time consuming ... onto their media," said Christina Austin - CEO of Pixel Film Studios. , ... easily add stylish color grades to their footage. A LUT is a Lookup Table ...
(Date:5/28/2016)... ... 2016 , ... In a part of the city where’s it’s easy to spot the neon ... is hoping to attract diners with a taste for real food. , On ... doors to Cornerstone Grill, an urban casual restaurant focusing on dishes made by hand with ...
(Date:5/27/2016)... ... ... Two director-level employees of Horizon Blue Cross Blue Shield of New Jersey ... The award recognizes businesswomen who excel in their fields and who have made ... (Managed Long-Term Services and Supports) Program at Horizon NJ Health and Theresa Ponton, Director ...
Breaking Medicine News(10 mins):